↓ Skip to main content

Dove Medical Press

A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease

Overview of attention for article published in Biologics: Targets & Therapy, June 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
53 Mendeley
Title
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease
Published in
Biologics: Targets & Therapy, June 2013
DOI 10.2147/btt.s34939
Pubmed ID
Authors

Johan Bennett, Christophe Dubois

Abstract

The development of coronary stents represents a major step forward in the treatment of obstructive coronary artery disease since the introduction of percutaneous coronary intervention. The initial enthusiasm for bare metal stents was, however, tempered by a significant incidence of in-stent restenosis, the manifestation of excessive neointima hyperplasia within the stented vessel segment, ultimately leading to target vessel revascularization. Later, drug-eluting stents, with controlled local release of antiproliferative agents, consistently reduced this need for repeat revascularization. In turn, the long-term safety of first-generation drug-eluting stents was brought into question with the observation of an increased incidence of late stent thrombosis, often presenting as myocardial infarction or sudden death. Since then, new drugs, polymers, and platforms for drug elution have been developed to improve stent safety and preserve efficacy. Development of a novel platinum chromium alloy with high radial strength and high radiopacity has enabled the design of a new, thin-strut, flexible, and highly trackable stent platform, while simultaneously improving stent visibility. Significant advances in polymer coating, serving as a drug carrier on the stent surface, and in antiproliferative agent technology have further improved the safety and clinical performance of newer-generation drug-eluting stents. This review will provide an overview of the novel platinum chromium everolimus-eluting stents that are currently available. The clinical data from major clinical trials with these devices will be summarized and put into perspective.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 53 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 25%
Student > Master 13 25%
Student > Ph. D. Student 5 9%
Student > Bachelor 3 6%
Professor 3 6%
Other 9 17%
Unknown 7 13%
Readers by discipline Count As %
Medicine and Dentistry 14 26%
Engineering 13 25%
Agricultural and Biological Sciences 5 9%
Chemical Engineering 3 6%
Chemistry 3 6%
Other 4 8%
Unknown 11 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 July 2013.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Biologics: Targets & Therapy
#214
of 274 outputs
Outputs of similar age
#150,411
of 206,928 outputs
Outputs of similar age from Biologics: Targets & Therapy
#5
of 6 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,928 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one.